Glioblastoma under siege of Therapeutics and Research: "Advancements and Future Targets".

Glioblastoma under siege of Therapeutics and Research: "Advancements and Future Targets". Curr Drug Metab. 2020 Apr 07;: Authors: Chavda V, Patel V, Yadav D, Shah J, Patel S, Jin JO Abstract Glioblastoma, most common primary brain tumor has been recognized as a one of the most lethal and fatal human tumors, which has a dismal prognosis with an average life duration not more than 15 months and end up with surgery and radiotherapy which ideally suggest a hope to escape an underprivileged diagnosis. As aimed at, numerous strategies were currently believed to upgrade in-vivo and in-vitro models with the definite goal of researching new molecular abnormal pathways, suitable for targeting by different of therapeutic approaches, including novel drugs, delivery systems and immunotherapy strategies with better kind of tumor biology of brain tumors that setup new directions in new multimodal therapy by aiming the molecular pathways involved in tumor initiations and progression. The goal of this review is to describe the tumor pathophysiology, neurodegeneration mechanism and signaling pathways and future targets. Current review critically focuses on key features of glioma to provide up-to-date summary of the advancement needed in current diagnosis and therapeutics and the role of nanoparticulate system Graphene Quantum Dots (GQDs) used as a future medicine and scope of drugless treatment. PMID: 32268863 [PubMed - as supplied by publishe...
Source: Current Drug Metabolism - Category: Drugs & Pharmacology Authors: Tags: Curr Drug Metab Source Type: research